Investing in Precision Medicine Panel

Improving Outcomes through a Patient-Tailored Approach

Wednesday November 17, 2:00PM EST

This panel discusses current trends in precision medicine. Topics may include:

  • How investors assess precision medicine technologies and applications in diagnostics, drug discovery and treatment plans
  • Which indications investors believe are showing the most promise – genetic disorders, orphan diseases, oncology, etc.
  • Investing in individualized treatments (such as CAR-T) and the scalability challenges of autologous vs allogeneic/xenogeneic off-the-shelf treatments
  • The regulatory challenges some of these technologies face, whether to ensure individual privacy from genomics databanks or to prevent potential harmful side effects from therapeutics such as CRISPR technologies

Precision medicine has proven to produce more effective treatments in multiple indications by tailoring medical treatment to the individual and their disease. Additionally, early detection of disease has improved outcomes for many patients. Panelists will discuss where the ¬eld is heading and what unique challenges companies in this area will face.


Amit Jolly, Investor, Carpe Biosciences (Moderator)

Carpe Biosciences is a multibillion family office investing in private and public companies. Led by Amit Jolly, our team identifies and invests in companies offering differentiated therapeutic advances with a defined execution strategy. Carpe Biosciences seeks long-term investment positions across the capital raising calendar.

Request a Meeting

Diana Saraceni, Founder, Managing Director, Panakes Partners

Founder of Panakes, Diana has over 20 years of international experience in managing Venture Capital investment funds, through which she invested in over 60 start-ups across Europe. After several years of experience in the strategic consultancy sector at A.T. Kearney, Diana worked as Senior Advisor in the Investment Banking division of Lazard. In 2001 she co-founded 360 Capital Partners, a leading pan-European Venture Capital firm. She is a member of several national and international committees (EU and US) for the selection and promotion of innovative start-ups. She has also co-founded and chaired the International Venture Club, an association that brings together the main European venture capital firms. She is frequently involved as Scientific Advisor to Life Sciences conferences and acting in or chairing juries for the allocation of public funds at Italian, European and US level (i.e. Premio Marzotto, Life Star Awards, EIC H2020 and National Cancer Institute-SBIR initiative).

Request a Meeting

Beth Hoffman, President & CEO, Origami Therapeutics

I’m a Research and Development Executive in drug discovery and development, with a consistent record of successfully generating and implementing research strategies for multiple disease areas from early target identification and validation through clinical Proof-of-Concept (POC), increasing quality, productivity and innovation.

I have extensive expertise in evaluating partnership and investment opportunities for small molecules, biologics and nucleic acid therapeutics.

I’m an internationally recognized scientist generating cutting-edge research in neuroscience, respiratory diseases, regenerative medicine, pharmacology, molecular biology, and cellular signaling pathways, with a strong publication record.

Request a Meeting

Randy Pritchard, CEO, Pillar Biosciences

Mr. Randy Pritchard is CEO of Pillar Biosciences. He has more than 24 years of healthcare experience as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, and driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics. He completed his undergraduate studies at Purdue University and his MBA at Indiana Wesleyan University.

Request a Meeting

Bharat Srinivasa, Investment Team, Amplitude Ventures

Bharat Srinivasa is a Principal at Amplitude Venture Capital, a firm focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Amplitude is co-managing BDC Capital’s Healthcare Venture Fund, which invests in transformative Canadian companies that are leveraging technology to reduce healthcare costs while improving patient health.